Therapeutic Antibodies: Bench to Market

Webinar Series of the Chinese Antibody Society

Upcoming Webinar

Register today to reserve your seat

FREE FOR EVERYONE

Antibody treatments have been available for over 2 decades for non-oncology indications, particularly in immunology. In this presentation, Dr. Aliprantis will use case studies from his clinical practice and drug development experience to highlight the antibody characteristics that are most important to patients and how these drugs can be delivered to patients faster. He will review how technologic advances in systems modeling, and antibody discovery and optimization, have led to next generation candidates and approvals with improved benefit for patients.

Sign in to Register

Recent Webinars

Sign in to view recordings

Targeting mutation-associated neoantigens using antibodies as therapeutics

10/26/2024

Dr. Sandra Gabelli

突变相关肿瘤新抗原(MANAs)在癌症免疫治疗中被视为极具潜力的靶点，因为它们只在肿瘤细胞中表达，避免了对正常组织的损伤。这一独特特性为开发靶向MANAs的抗体药物开辟了新的治疗路径。抗体疗法的精准性为难治性肿瘤提供了新的希望。近年来，冷冻电子显微镜（CryoEM）技术的发展，进一步推动了抗体设计的进步。CryoEM能够以近原子分辨率揭示抗体与MANAs的相互作用，帮助科学家深入理解抗体结合位点及其机制，为抗体优化提供了关键的结构性见解。 通过这种方式，研究人员能够开发出更高效且特异性更强的抗体药物。这不仅可以显著提升抗癌疗效，还能够减少副作用，进而提高患者的生活质量。随着CryoEM技术的进步，抗体药物开发的速度和精度有望进一步提升，使靶向突变相关新抗原的治疗策略成为精准癌症治疗中的重要组成部分。

target biology
The Highs, Lows and Resurgence of ADCs

09/28/2024

Dowdy Jackson

Antibody drug conjugates (ADCs) are rapidly becoming the standard of care for cancer treatment. This has led to a resurgence of investment in the development of ADCs. ADC focused merger/acquisitions and partnership totaled almost $100 billion USD in 2023. This is more than three times the value of similar ADC …

antibody discovery
A Safer and More Efficacious Cell Therapy for Solid Tumors

08/24/2024

Dr. Cheng Liu

Solid tumors represent approximately 90% of all cancers. Chimeric antigen receptor T (CAR-T) cells have shown promising outcomes in the treatment of hematologic malignancies. However, CAR-T cell therapy in solid tumor treatment has been significantly hindered, due to the complex tumor microenvironment (TME) in solid tumors affects the proliferation and …

target biology
PROTABs A Tool For Leveraging E3 Ubiquitin ligases As Cell Surface Protein Degraders

06/29/2024

Dr. Hadir Marei

Protein ubiquitylation is central to proper cellular functioning by providing a fine-tuning mechanism that controls protein activity, subcellular localization and turnover. Canonical protein ubiquitylation involves a three-step enzymatic cascade with substrate specificity dictated by E3 ubiquitin ligases that transfer ubiquitin to a target protein. As such, advances allowing the regulation …

target biology
Icon